monkey survived each outbreak.
On 1 July, an institute committee set up after the second outbreak published its findings in the online version of the Japanese-language journal Primate Research (Kyoto University Primate Research Institute Disease Control Committee Primate Res. 26, 69-71; 2010) . The committee tested blood, faeces and tissues from the diseased monkeys for 6 bacteria and 16 viruses. The tests, which included PCR analysis, turned up nothing that could explain the deaths. François Villinger, director of pathology at the Yerkes National Primate Research Center in Atlanta, Georgia, says that Japanese laboratories tend to have excellent diagnostic capabilities: "Therefore I have confidence in the fact that the illness is probably not due to any of the known agents inducing haemorrhagic fevers. "
PRI director Tetsuro Matsuzawa spoke out against suggestions in the local media that the disease could spread to humans or other animals. At the 7 July press conference, he stressed that none of the other primate species at the institute, which houses more than 1,200 animals from 13 species, including chimpanzees, marmosets and crabeating macaques, has contracted the syndrome. The humans who handled the monkeys also show no symptoms. "I don't like the headlines in the news media, " he says. "We think that the haemorrhagic syndrome is due to a species-specific pathogen of the Japanese monkeys. "
Matsuzawa says that the institute did not publish its findings earlier because it feared causing panic in the wider population. Cases are still occurring, but following the use of disinfectants and the isolation of sick monkeys, the pace has Questions raised over Korean torpedo claims Social scientists and engineers started the most businesses that were not based on patented inventions, but such ventures were also prevalent among biomedical and physical scientists (see 'Unexpected entrepreneurs').
"There is a lot of stuff that academics are realizing isn't patentable but they can commercialize for themselves by starting a company, " says Scott Shane, an economist at Case Western Reserve University in Cleveland, Ohio, and a co-author of the study. Because surveys of entrepreneurial activity -including government assessments -typically focus on patent activity, they may be significantly underestimating academics' efforts, he notes.
The study also says that universities' technology-transfer offices (TTOs) are "failing to help" a sizeable proportion of academic entrepreneurs. "If you aren't measuring [the full range of activities] you can't promote them," says Shane. "All the policies and approaches focus on the formal intellectual-property system, which means we are missing a big part of the iceberg that is under the water." Ashley Stevens, president of the Association of University Technology Managers, calls the study "a significant new piece of data". But he says that TTOs do help academic entrepreneurs outside the formal intellectual-property system. A major barrier to more support is that, unlike businesses started inside the system, those started without patents are less likely to provide the university with a financial return, he adds.
Yet the survey found no discernible difference in respondents' financial return between businesses started with and without patents, although those businesses not based on patents were more likely to fail.
The study comes as the US government is shaping its policy on the commercialization of federally funded research. The Office of Science and Technology Policy put out a call for information earlier this year, and is promising to use the results to help identify a set of "promising practices" that will encourage technology commercialization, says Tom Kalil, the office's deputy director for policy. "These include entrepreneurship education for faculty and students, proof-ofconcept funding, standardized intellectualproperty agreements, and policies that allow faculty to take 'industrial leave' to start up a company. " Some experts say that governments and universities are still right to focus on patent-based academic entrepreneurship. Businesses built on inventions tend to need more support to establish themselves, and can potentially generate the greatest returns, says Mark Schankerman, who studies entrepreneurship at the London School of Economics. "It is getting out a new drug, not a new consultancy company, which is going to make the larger contribution to the economy and society," he says. slowed to one case in May and one in June. Matsuzawa is holding back some data for a more detailed future publication and would not answer Nature's questions about whether his group is also probing possible environmental causes, which bacteria and viruses have been tested for, and what analysis of the two surviving monkeys has revealed.
By screening the 790 remaining Japanese macaques for other viruses and bacteria and running genetic tests, Matsuzawa hopes to pin down the cause of the syndrome and to create a test for early diagnosis. He says that he is looking for collaborators, and animalpathogen researchers contacted by Nature are certainly eager to learn more about the illness. Primate disease specialist Sonia Altizer of the University of Georgia in Athens wonders whether any of the animals were recently captured in the wild, where they could have picked up the infection, and whether animals were housed singly or in groups. "Knowing the possible contacts between animals and the chronological pattern of illness or deaths might also help determine whether this was indeed an infectious agent, and the possible routes of transmission, " she says.
She also asks what measures the human workers were taking before the outbreaks to minimize transmission of infectious agents between monkeys and humans. "Presumably there would be some pretty careful measures in place that would limit human exposure to any contaminant or pathogen, " she says, "so saying that humans are not susceptible to me seems premature. "
